NewEdge Wealth LLC Acquires 3,472 Shares of Stryker Corporation $SYK

NewEdge Wealth LLC boosted its holdings in Stryker Corporation (NYSE:SYK) by 44.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 11,257 shares of the medical technology company’s stock after purchasing an additional 3,472 shares during the period. NewEdge Wealth LLC’s holdings in Stryker were worth $3,957,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. United Financial Planning Group LLC bought a new stake in Stryker in the third quarter worth $27,000. CGC Financial Services LLC bought a new stake in Stryker in the fourth quarter worth $29,000. Strive Asset Management LLC bought a new stake in Stryker in the third quarter worth $30,000. ANTIPODES PARTNERS Ltd bought a new stake in Stryker in the third quarter worth $34,000. Finally, Copia Wealth Management lifted its stake in Stryker by 181.6% in the third quarter. Copia Wealth Management now owns 107 shares of the medical technology company’s stock worth $40,000 after purchasing an additional 69 shares during the last quarter. 77.09% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on SYK. UBS Group lowered their price target on shares of Stryker from $400.00 to $380.00 and set a “neutral” rating for the company in a research note on Tuesday, March 17th. Wall Street Zen raised shares of Stryker from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Jefferies Financial Group reaffirmed a “buy” rating and set a $465.00 price objective on shares of Stryker in a research note on Wednesday, March 4th. Deutsche Bank Aktiengesellschaft set a $315.00 price objective on shares of Stryker in a research note on Friday, May 1st. Finally, Barclays lowered their price objective on shares of Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a research note on Monday, May 4th. Sixteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Stryker currently has an average rating of “Moderate Buy” and a consensus target price of $395.48.

Stryker Stock Performance

Shares of NYSE:SYK opened at $282.85 on Tuesday. The company has a market cap of $108.33 billion, a price-to-earnings ratio of 32.74, a price-to-earnings-growth ratio of 1.80 and a beta of 0.80. The company has a 50-day moving average price of $336.33 and a 200-day moving average price of $353.81. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $404.87.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). The firm had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business’s revenue was up 2.6% on a year-over-year basis. During the same period last year, the company posted $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, equities analysts anticipate that Stryker Corporation will post 14.98 EPS for the current year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s dividend payout ratio is presently 40.74%.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.